PA arld DEB/NICHD/NIH, Bethesda. MD. USA. G~rls with Turner syndrome (TS) are short and lack endogenous estrogen. Our aim in this study was t o evaluate the behavioral effects of continuous growth hormone (GH), ethinyl estradiol (E), or placebo (P) treatment in TS girk. Subjects were recruited from an ongoing randomized trial, consisting of 4 TS treatment groups: l.E (25-50 ng/kg/day until age 12,100 ng/kg, ages 12-14, 200-800 ng/kg/day above 1 4 ), 2. GH (0.1 mg/kg, SQ tiw). 3. E, as above, plus GH, and 4. P until age 12, followed by E, as above. The psychological assessment (at baseline and ycy& intervals) included 2 tests: The Child Behavior Checklist (CBCL), a parental report of social and behavior problems, and the Piers-Harris Self-concept Scale (child reported), a test of overall self-concept. Results were analyzed from 106 girls with TS, ages 5-16 years, with treatment durations of 0-5 years. Basellne karyotype, age. SES level,and growth rate were simllar in all 4 groups. Multiple regressions explored the association between treatment group, duration, and the psychological measures for TS girls treated early (prior t o age 11.5) or late (after age 11.5). In the early-treated girls,no associations between type or duration of treatment and the psychological measures were revealed. In the late-treated girls,longer E treatment was associated with improved ratings on the Piers Total self-concept scale (p-.0001). Longer GH treatment was associated with more positive ratings on the intellectual and physical subscales (p=.0001). On the CBCL.longer GH treatment was associated with decreased, negative Internalizing and Externallzing (p=.004) behaviors and improved school functioning (p=.0001). We conclude: (1) for early-treated TS girls.treatment with E.GH,or P had no significant effects on the behavioral variables and (2) for late-treated TS girls,both E and GH treatment was associated with improved behavioral outcomes. a n o r e x i a n e r i o s a , o b e s i t y , d i a b e t e s , ~H -t h e r a~y ; a c r o m e g a l y a n d c i r r h o s i s . I n s h o r t , s l o w l y g r o w l n g c h i l d r e n GH-BP c o r r e l a t e d n e g a t i v e l y w i t h m e a n G H -p u l s e a m p l i t u d e a n d i n t e g r a t e d c o n c e n t r a t i o n . GH p u l s a t i l i t y i s h i g h i n n e w b o r n s , f a s t i n g , a n o r e x i a n e r v o s a d i a b e t e s a c r o m e g a l y a n d c i r r h o s i s .
a n o r e x i a n e r i o s a , o b e s i t y , d i a b e t e s , ~H -t h e r a~y ; a c r o m e g a l y a n d c i r r h o s i s . I n s h o r t , s l o w l y g r o w l n g c h i l d r e n GH-BP c o r r e l a t e d n e g a t i v e l y w i t h m e a n G H -p u l s e a m p l i t u d e a n d i n t e g r a t e d c o n c e n t r a t i o n . GH p u l s a t i l i t y i s h i g h i n n e w b o r n s , f a s t i n g , a n o r e x i a n e r v o s a d i a b e t e s a c r o m e g a l y a n d c i r r h o s i s .
GH-BP i s l o w i n ' a l l , t h e s & conditions. GH p u l s a t j l i t y i s l o w , a n d GH-BP i s h i g h , I n G H -t h e r a p y a n d o b e s l t y . N e g a t i v e correlation o E GH p u 1 s a t ; i l l t y w i t h G H -B P , e x i s t s a c r o s s , t h e m a m m a l i a n c l a s s w l t h i n c r e a s i n g p u l s a t l l l t y i n r a b b i t < man < E e m a l e r a t < m a l e r a t < g u i n e a p l g , , w h e r e a s GH-BP l e v e l s a n d l i v e r m e m b r a n e ' s GH-R d e c r e a s e I n t h e same o r d e r . N e w b o r n r a t s h a v e h i g h GH p u l s a t i l i t y a n d l o w GH-R a n d GH-BP, w h e r e a s o b e s e r a t s h a v e l o w GH l e v e l s a n d h i g h G N -r e c e p t o r s . I t i s c o n c l u d e d t h a t t h e p a t t e r n o f GH p r o f i l e s i s t h e m a j o r d e t e r m i n a n t o f t h e GH-R / GH-BP, t h a t t h e v a r i o u s p h y s i o l o g i c a l a n d p a t h o l o g i c a l c o n d i t i o n s r e g u l a t e p r l m a r i l y t h e p a t t e r n o f GH p u l s a t i l i t y , w h i c h , i n t u r n r e u l a t e s t h e GH-R / GH-BP, a n d t h e r e b y e x e r t t h e s p e c i E i & Seaaonal v a r i~t i o n i n growth rate is clocu~neiite~l i n ~norlnal clril<l~en, liowevcr conllict~iig reports have been publlslied r e g a r~l i l~g ~l i~l d~e~i tre:ltetl witli growtli horlilolie (CH). We analyzed thr growth rate of clrllil~cn who wcre treated witli GI1 :lnd eiirollcd in the NCCS for C l l deficiency 01 ~<llnp:ltl~ic hhort \tntule. 011ly pre-pubertal children (inales <I I y.o., f e l l i~l e s 510 y.0.) were ili~luded. TWOthirds of the (late points were for male patients. A gluwtli rate wa\ assigned to a aeaaoli bnsed on thc month i n which the ~nidpoint ol' the ~litclvnl fell. Winter was defined as the 3 months o f December, Jnliuary, slid February, 2nd so OII Graphical representation of these equations shows that group 1 undergoes a relatively quick CUG which stabilizes at -0.5 SDS alter two years of therapy. Group 2 catches up .at a lower rate and stabilizes one year later, but reaches a higher endpoint at +0.4 SDS. These equallons provide the clinician with a reference instrument for assessing the elficacy of a growth promoting therapy. p l s demonstrated a stgnUlcantly poorer response t o C H In the flrst year as compared to IGHD. unlike previous reports. Although PNET pts, as a group. conllnued to show posltlve growl11 veloclly Z scores. H t Z scores (as shown by others1 dld not Increase slgnlflcanlly. Growth response was not correlaled to age at dlagnosls of PNET, n o r l o age a1 GI4 Rx. n o r l o durallon between dlagnosls a n d lnltlatlon of GH Rx. Crown-rump measurements would lndlcale t h a l impalred splnal growth does not account for lhe modest response to C H durlng the first year. A possible cxplanatlon I s (ha1 chemotherapeutic agents can. In certaln circumstances. cause relative insensilivity to growth faclors.
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